BLZ-945
| Code | Size | Price |
|---|
| SYN-1197-M100 | 100 mg | Enquire |
Quantity:
| SYN-1197-M050 | 50 mg | Enquire |
Quantity:
| SYN-1197-M001 | 1 mg | £197.00 |
Quantity:
| SYN-1197-M005 | 5 mg | £420.00 |
Quantity:
| SYN-1197-M010 | 10 mg | £654.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
BLZ945
Appearance:
Solid.
CAS:
953769-46-5
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1
InChiKey:
ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Long Description:
Chemical. CAS: 953769-46-5. Formula: C20H22N4O3S. MW: 398.5. BLZ945 is an orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R) inhibitor, which inhibits CSF-1R activity with an IC(50) of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor beta (PDGFRbeta ) as well as more than 200 additional kinases, confirming the selectivity of the compound.
Molecular Formula:
C20H22N4O3S
Molecular Weight:
398.5
Package Type:
Plastic Vial
Product Description:
BLZ945 is an orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R) inhibitor, which inhibits CSF-1R activity with an IC(50) of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor beta (PDGFRbeta ) as well as more than 200 additional kinases, confirming the selectivity of the compound.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011) | CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013) | CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013) | Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013) | Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
Related Products
| Product Name | Product Code | Supplier | BLZ-945 | AG-CR1-3609 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|